Patient-Reported Outcomes With Episoft® AC SPF 50+, a Ceramide-Based Moisturizer, in Acne-Related Post-procedural Care: A Real-World Multicenter Observational Study From India (PROCEED Study).
5 affiliations
- 1Dermatology, Centre for Skin, New Delhi, IND.
- 2Dermatology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, IND.
- 3Dermatology, Amrita Institute of Medical Sciences and Research Centre, Kochi, IND.
- 4Dermatology, DERMA HUB Clinic, Mumbai, IND.
- 5Global Medical Affairs, Glenmark Pharmaceuticals Limited, Mumbai, IND.
Abstract
Background
Post-procedural skin barrier disruption following acne-related dermatological procedures causes significant patient discomfort and heightens ultraviolet (UV) sensitivity. Ceramide-based formulations with broad-spectrum photoprotection can address barrier repair and sun protection factor (SPF) in a single step. However, patient-reported evidence supporting their use in this setting is still limited.Methods
A retrospective, multicenter, observational study was conducted across 477 dermatology centers in India after ethics approval. Patients aged 18-45 years prescribed Episoft® AC SPF 50+ (a ceramide-based moisturizer with broad-spectrum SPF 50+ photoprotection; Glenmark Pharmaceuticals Limited, Mumbai, India) for at least seven days following acne-related dermatological procedures were included. Post-procedural skin barrier disruption was classified into four levels (none/minimal, mild, moderate, severe) based on procedure type. Patient-reported outcome measures (PROMs) were assessed at Day 7 using 10-point numeric scales. Primary endpoints were reduction in dryness and burning/stinging sensation. Secondary endpoints were reduction in skin itching, reduction in skin redness, soothing effect, acne worsening, overall satisfaction, willingness to continue use, and willingness for future procedures. Improvement responses were categorized as complete (9-10), moderate (6-8), mild (3-5), or none (1-2). Acne worsening used a reversed scale, in which a score of 1-2 indicated no/minimal worsening (favorable).Results
A total of 2,066 patients (55.3% (n = 1,143) female; modal age group 26-30 years, 42.7% (n = 882)) were enrolled. The top three procedures were chemical peel (56.7%; n = 1,172), Q-switched laser toning (10.9%; n = 226), and microneedling (8.9%; n = 183). Barrier disruption was predominantly moderate (56.7%; n = 1,172), with severe disruption in 10.8% (n = 223). On Day 7, complete improvement was reported by 61.2% (n = 1,265) for dryness (mean ± SD: 8.64 ± 1.14) and 58.6% (n = 1,210) for burning/stinging (mean ± SD: 8.63 ± 1.14). Complete improvement rates for secondary endpoints were skin itching 61.4% (n = 1,268), skin redness 62.1% (n = 1,283), and soothing effect 61.2% (n = 1,264). Overall extreme satisfaction was reported by 62.6% (n = 1,293), willingness to continue use by 65.6% (n = 1,356), and willingness for future procedures by 67.2% (n = 1,388). No worsening of acne was reported by 67.9% (n = 1,403) of patients. There were no adverse events reported during the study.Conclusion
In this large, real-world multicenter study, Episoft® AC SPF 50+, a ceramide-based moisturizer with SPF 50+, was associated with substantial patient-reported symptom relief, high satisfaction, and minimal acne worsening across diverse acne-related dermatological procedures and barrier severity levels, along with an excellent safety profile. These findings, together with emerging patient-reported outcome-based evidence for combined moisturizer-plus-SPF products, support routine inclusion of ceramide-based SPF 50+ moisturization in post-procedural skincare regimens for acne-related procedures.
Related
- Feasibility and Operator-Reported Utility of Transesophageal Lung Ultrasound As an Adjunct to Resuscitative Transesophageal Echocardiography in the Evaluation of Shock: A Multicenter Observational Study
- Associations of alveolar ridge morphology with denture base extension and patient-reported outcomes in complete denture wearers: a quantitative observational study
- Clinical outcomes of angina treatment in coronary microvascular dysfunction: results of a multicenter observational study
- Frailty is associated with prolonged hospitalization and inferior patient-reported outcomes after acute quadriceps tendon rupture: A multicenter cohort study.
- The effect of symptomatic extra-articular manifestations of rheumatoid arthritis on disease activity and patient-reported outcomes: a cross-sectional and observational study.
BibTeX
@article{nakra2026patientreported,
title = {{Patient-Reported Outcomes With Episoft® AC SPF 50+, a Ceramide-Based Moisturizer, in Acne-Related Post-procedural Care: A Real-World Multicenter Observational Study From India (PROCEED Study).}},
author = {Gaurav Nakra and Maitreyee Panda and Soumya Jagadeesan and Sama Rais and Ashwin Balasubramanian and Prajakta Bhosale and Dhiraj Dhoot and Saiprasad Patil},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116524},
url = {https://europepmc.org/article/MED/42898708},
note = {CC BY},
}
RIS
TY - JOUR
TI - Patient-Reported Outcomes With Episoft® AC SPF 50+, a Ceramide-Based Moisturizer, in Acne-Related Post-procedural Care: A Real-World Multicenter Observational Study From India (PROCEED Study).
AU - Gaurav Nakra
AU - Maitreyee Panda
AU - Soumya Jagadeesan
AU - Sama Rais
AU - Ashwin Balasubramanian
AU - Prajakta Bhosale
AU - Dhiraj Dhoot
AU - Saiprasad Patil
PY - 2026
DA - 2026/09/19
JO - Cureus
DO - 10.7759/cureus.116524
UR - https://europepmc.org/article/MED/42898708
AB - Background Post-procedural skin barrier disruption following acne-related dermatological procedures causes significant patient discomfort and heightens ultraviolet (UV) sensitivity. Ceramide-based formulations with broad-spectrum photoprotection can address barrier repair and sun protection factor (SPF) in a single step. However, patient-reported evidence supporting their use in this setting is still limited.Methods A retrospective, multicenter, observational study was conducted across 477 dermatology centers in India after ethics approval. Patients aged 18-45 years prescribed Episoft® AC SPF 50+ (a ceramide-based moisturizer with broad-spectrum SPF 50+ photoprotection; Glenmark Pharmaceuticals Limited, Mumbai, India) for at least seven days following acne-related dermatological procedures were included. Post-procedural skin barrier disruption was classified into four levels (none/minimal, mild, moderate, severe) based on procedure type. Patient-reported outcome measures (PROMs) were assessed at Day 7 using 10-point numeric scales. Primary endpoints were reduction in dryness and burning/stinging sensation. Secondary endpoints were reduction in skin itching, reduction in skin redness, soothing effect, acne worsening, overall satisfaction, willingness to continue use, and willingness for future procedures. Improvement responses were categorized as complete (9-10), moderate (6-8), mild (3-5), or none (1-2). Acne worsening used a reversed scale, in which a score of 1-2 indicated no/minimal worsening (favorable).Results A total of 2,066 patients (55.3% (n = 1,143) female; modal age group 26-30 years, 42.7% (n = 882)) were enrolled. The top three procedures were chemical peel (56.7%; n = 1,172), Q-switched laser toning (10.9%; n = 226), and microneedling (8.9%; n = 183). Barrier disruption was predominantly moderate (56.7%; n = 1,172), with severe disruption in 10.8% (n = 223). On Day 7, complete improvement was reported by 61.2% (n = 1,265) for dryness (mean ± SD: 8.64 ± 1.14) and 58.6% (n = 1,210) for burning/stinging (mean ± SD: 8.63 ± 1.14). Complete improvement rates for secondary endpoints were skin itching 61.4% (n = 1,268), skin redness 62.1% (n = 1,283), and soothing effect 61.2% (n = 1,264). Overall extreme satisfaction was reported by 62.6% (n = 1,293), willingness to continue use by 65.6% (n = 1,356), and willingness for future procedures by 67.2% (n = 1,388). No worsening of acne was reported by 67.9% (n = 1,403) of patients. There were no adverse events reported during the study.Conclusion In this large, real-world multicenter study, Episoft® AC SPF 50+, a ceramide-based moisturizer with SPF 50+, was associated with substantial patient-reported symptom relief, high satisfaction, and minimal acne worsening across diverse acne-related dermatological procedures and barrier severity levels, along with an excellent safety profile. These findings, together with emerging patient-reported outcome-based evidence for combined moisturizer-plus-SPF products, support routine inclusion of ceramide-based SPF 50+ moisturization in post-procedural skincare regimens for acne-related procedures.
SN - 2168-8184
ER -